The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Open accessAbstract
BACKGROUND: The amyloid fibril deposits that cause systemic amyloidosis always contain the nonfibrillar normal plasma protein, serum amyloid P component (SAP). The drug (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) efficiently depletes SAP from the plasma but leaves some SAP in amyloid deposits that can be specifically targeted by therapeutic IgG anti-SAP antibodies. In murine amyloid A type amyloidosis, the binding of these antibodies to the residual SAP in amyloid deposits activates complement and triggers the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. METHODS: We conducted an open-label, single-dose-escalation, phase 1 trial involving 15 patients with systemic amyloidosis. After first using CPHPC to deplete circulating SAP, we infused a fully humanized monoclonal IgG1 anti-SAP antibody. Patients with clinical evidence of cardiac involvement were not included for safety reasons. Organ function, inflammatory markers, and amyloid load were monitored. RESULTS: There were no serious adverse events. Infusion reactions occurred in some of the initial recipients of larger doses of antibody; reactions were reduced by slowing the infusion rate for later patients. At 6 weeks, patients who had received a sufficient dose of antibody in relation to their amyloid load had decreased liver stiffness, as measured with the use of transient elastography. These patients also had improvements in liver function in association with a substantial reduction in hepatic amyloid load, as shown by means of SAP scintigraphy and measurement of extracellular volume by magnetic resonance imaging. A reduction in kidney amyloid load and shrinkage of an amyloid-laden lymph node were also observed. CONCLUSIONS: Treatment with CPHPC followed by an anti-SAP antibody safely triggered clearance of amyloid deposits from the liver and some other tissues. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01777243.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moon, J. C., Messroghli, D. R., Kellman, P., Piechnik, S. K., Robson, M. D., Ugander, M., Gatehouse, P. D., Arai, A. E., Friedrich, M. G., Neubauer, S., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-92 · Cited by 1,136
Self-citationAcute viral hepatitis increases liver stiffness values measured by transient elastography
Arena, U., Vizzutti, F., Corti, G., Ambu, S., Stasi, C., Bresci, S., Moscarella, S., Boddi, V., Petrarca, A., Laffi, G., et al. (2008) · Hepatology · doi:10.1002/hep.22007 · Cited by 754
Self-citationPepys, M. B. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 559
Self-citationTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Self-citationEvaluation of Systemic Amyloidosis by Scintigraphy with123I-Labeled Serum Amyloid P Component
Hawkins, P. N., Lavender, J. P., & Pepys, M. B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008233230803 · Cited by 533
Self-citationAntibodies to human serum amyloid P component eliminate visceral amyloid deposits
Bodin, K., Ellmerich, S., Kahan, M. C., Tennent, G. A., Loesch, A., Gilbertson, J. A., Hutchinson, W. L., Mangione, P. P., Gallimore, J. R., Millar, D. J., et al. (2010) · Nature · doi:10.1038/nature09494 · Cited by 341
Self-citationBanypersad, S. M., Sado, D. M., Flett, A. S., Gibbs, S. D. J., Pinney, J. H., Maestrini, V., Cox, A. T., Fontana, M., Whelan, C. J., Wechalekar, A. D., et al. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.978627 · Cited by 335
Self-citation(1979) · PubMed Central · Cited by 271
Amyloid P-component is a constituent of normal human glomerular basement membrane.
Dyck, R. F., Lockwood, C. M., Kershaw, M., McHugh, N., Duance, V. C., Baltz, M. L., & Pepys, M. B. (1980) · The Journal of experimental medicine · doi:10.1084/jem.152.5.1162 · Cited by 216
Self-citationAmyloid P component is located on elastic fibre microfibrils in normal human tissue
Breathnach, S. M., Melrose, S. M., Bhogal, B., de Beer, F. C., Dyck, R. F., Tennentt, G., Black, M. M., & Pepys, M. B. (1981) · Nature · doi:10.1038/293652a0 · Cited by 192
Self-citation
Cited by
Messroghli, D. R., Moon, J. C., Ferreira, V. M., Grosse-Wortmann, L., He, T., Kellman, P., Mascherbauer, J., Nezafat, R., Salerno, M., Schelbert, E. B., et al. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-017-0389-8 · Cited by 1,727
Self-citationTransthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Self-citationA new staging system for cardiac transthyretin amyloidosis
Gillmore, J. D., Damy, T., Fontana, M., Hutchinson, M., Lachmann, H. J., Martinez-Naharro, A., Quarta, C. C., Rezk, T., Whelan, C. J., Gonzalez-Lopez, E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx589 · Cited by 776
Self-citationKittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
AL (Light-Chain) Cardiac Amyloidosis
Falk, R. H., Alexander, K. M., Liao, R., & Dorbala, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.053 · Cited by 649
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationAddressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-019-01760-6 · Cited by 484
Self-citationHereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Muchtar, E., Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dingli, D., Buadi, F. K., Grogan, M., Hayman, S. R., Kapoor, P., Leung, N., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751628 · Cited by 340
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment
Siddiqi, O. K., & Ruberg, F. L. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.07.004 · Cited by 333
Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Muchtar, E., Blauwet, L. A., & Gertz, M. A. (2017) · Circulation Research · doi:10.1161/circresaha.117.310982 · Cited by 327
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., et al. (2021) · Circulation: Cardiovascular Imaging · doi:10.1161/hci.0000000000000029 · Cited by 275
Self-citationMartinez-Naharro, A., Hawkins, P. N., & Fontana, M. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-s30 · Cited by 257
Self-citationRichards, D. B., Cookson, L. M., Barton, S. V., Liefaard, L., Lane, T., Hutt, D. F., Ritter, J. M., Fontana, M., Moon, J. C., Gillmore, J. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3128 · Cited by 136
Self-citationThe Development of Serum Amyloid P as a Possible Therapeutic
Pilling, D., & Gomer, R. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02328 · Cited by 92
Emerging Therapies in Transthyretin Amyloidosis – A New Wave of Hope After Years of Stagnancy?
Müller, M. L., Butler, J., & Heidecker, B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1695 · Cited by 74
The Basic Characteristics of the Pentraxin Family and Their Functions in Tumor Progression
Wang, Z., Wang, X., Zou, H., Dai, Z., Feng, S., Zhang, M., Xiao, G., Liu, Z., & Cheng, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01757 · Cited by 73
The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs
Pepys, M. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02382 · Cited by 67
Self-citationGertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635008 · Cited by 38
Klotz, S. A., Sobonya, R. E., Lipke, P. N., & Garcia-Sherman, M. C. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw166 · Cited by 22
The Paradoxical Effects of Serum Amyloid-P Component on Disseminated Candidiasis
Klotz, S. A., & Lipke, P. N. (2022) · Pathogens · doi:10.3390/pathogens11111304 · Cited by 5
“Removal of circulating SAP with miridesap (see below) followed by treatment with complement fixing monoclonal antibody to SAP led to clinical improvement in human amyloidosis [8].”
BackgroundAmyloGram reveals amyloidogenic potential in stroke thrombus proteomes
Kell, D. B., Doyle, K. M., Salcedo-Sora, J. E., Sekhar, A., Walker, M., & Pretorius, E. (2025) · Biochemical Journal · doi:10.1042/bcj20253317 · Cited by 4
Metadata
- Authors
- Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., Fontana, M., Moon, J. C., Pinzani, M., Gillmore, J. D., Hawkins, P. N., & Pepys, M. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-17
- Volume
- 373
- Issue
- 12
- Pages
- 1106-1114
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282508430
- Cited by
- 378
- References
- 23
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.